People: Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

27.71USD
1:39pm EDT
Price Change (% chg)

$-0.07 (-0.25%)
Prev Close
$27.78
Open
$27.67
Day's High
$27.92
Day's Low
$27.42
Volume
6,260,850
Avg. Vol
11,800,771
52-wk High
$31.14
52-wk Low
$22.16

Search Stocks

Summary

Name Age Since Current Position

Ian Read

 59 2011 Chairman of the Board, Chief Executive Officer

Frank D'Amelio

 55 2010 Chief Financial Officer, Executive Vice President - Business Operations

Mikael Dolsten

 54 2010 President - Worldwide Research and Development

Douglas Lankler

 47 2011 Executive Vice President, Chief Compliance and Risk Officer

Amy Schulman

 52 2012 Executive Vice President, General Counsel, Business Unit Lead - Consumer Healthcare

Charles Hill

 57 2010 Executive Vice President - Worldwide Human Resources

Freda Lewis-Hall

 58 2010 Executive Vice President, Chief Medical Officer

Anthony Maddaluna

 60 2013 Executive Vice President; President, Pfizer Global Supply

Laurie Olson

 49 2012 Executive Vice President - Strategy, Portfolio and Commercial Operations

Sally Susman

 51 2010 Executive Vice President - Policy, External Affairs and Communications

Olivier Brandicourt

 57 2012 President and General Manager - Pfizer Emerging Markets and Established Products

Geno Germano

 52 2010 President and General Manager - Pfizer Specialty Care and Oncology

John Young

 48 2012 President and General Manager - Primary Care

George Lorch

 72 2011 Lead Independent Director

Dennis Ausiello

 67 2006 Independent Director

M. Anthony Burns

 70 1988 Independent Director

W. Don Cornwell

 65 1997 Independent Director

Frances Fergusson

 68 2009 Independent Director

William Gray

 71 2000 Independent Director

Helen Hobbs

 60 2011 Independent Director

Constance Horner

 71 2010 Independent Director

James Kilts

 2007 Independent Director

Suzanne Nora Johnson

 55 2007 Independent Director

Stephen Sanger

 66 2009 Independent Director

Marc Tessier-Lavigne

 53 2011 Independent Director
» Insider Trading

Biographies

Name Description

Ian Read

 Mr. Ian C. Read is Chairman of the Board, Chief Executive Officer of Pfizer Inc. He has been Chairman of the Board and Chief Executive Officer of Pfizer since December 2011. President and Chief Executive Officer from December 2010. Previously, he served as Senior Vice President and Group President of the Worldwide Biopharmaceutical Businesses, which he led from 2006 through December 2010. In that role, he oversaw five global business units—Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets. Mr. Read began his career with Pfizer in 1978 as an operational auditor. He worked in Latin America through 1995, holding positions including Chief Financial Officer, Pfizer Mexico, and Country Manager, Pfizer Brazil. In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in 2002. Mr. Read later became accountable for operations in both the Africa/Middle East region and Latin America as well. Mr. Read serves on the Boards of PhRMA and the Partnership for New York City.

Frank D'Amelio

 Mr. Frank A. D'Amelio is Chief Financial Officer, Executive Vice President - Business Operations of Pfizer Inc., since December 2010. He was Senior Vice President and Chief Financial Officer from September 2007 until December 2010. Prior to joining Pfizer he was Senior Executive Vice President of Integration and Chief Administrative Officer of Alcatel-Lucent from November 2006 until August 2007. Chief Operating Officer of Lucent Technologies from January 2006 until November 2006. Chairman and Director of Zoetis. Director of Humana, Inc. and Chair of the Humana Audit Committee. He is a Director of the Independent College Fund of New Jersey.

Mikael Dolsten

 Dr. Mikael Dolsten, M.D., Ph.D., is President - Worldwide Research and Development of Pfizer Inc., since December 2010. He was President of Worldwide Research and Development since December 2010. Senior Vice President; President of Worldwide Research and Development from May 2010 until December 2010. Senior Vice President; President of Pfizer BioTherapeutics Research & Development Group from October 2009 until May 2010. He was Senior Vice President of Wyeth and President, Wyeth Research from June 2008 until October 2009. He was a Private Equity Partner at Orbimed Advisors, LLC from January 2008 until June 2008. Dr. Dolsten was Global Head, Corporate Division Pharma Research and Discovery, of Boehringer Ingelheim Corporation from 2003 to 2007.

Douglas Lankler

 Mr. Douglas M. Lankler is Executive Vice President, Chief Compliance and Risk Officer of Pfizer Inc., since February 2011. He served as Executive Vice President, Chief Compliance Officer from December 2010 until February 2011. Senior Vice President and Chief Compliance Officer from January 2010 until December 2010. Senior Vice President, Deputy General Counsel and Chief Compliance Officer from August 2009 until January 2010. Senior Vice President, Associate General Counsel and Chief Compliance Officer from October 2006 until August 2009. Prior to October 2006, Mr. Lankler held various positions of increasing responsibility within the Pfizer Legal Division.

Amy Schulman

 Ms. Amy W. Schulman is Executive Vice President, General Counsel, Business Unit Lead - Consumer Healthcare of Pfizer Inc. She has been Executive Vice President and General Counsel since December 2010 and Business Unit Lead, Consumer Healthcare for Pfizer since August 2012. Executive Vice President and General Counsel; President and General Manager, Nutrition from December 2010 until November 2012. Senior Vice President and General Counsel from June 2008 until December 2010. Ms. Schulman was a partner at the law firm of DLA Piper from 1997 until joining Pfizer in June 2008. Currently a Director of Zoetis and Chair of the Zoetis Corporate Governance Committee, Member of the Board of Directors of Wesleyan University and the Brooklyn Academy of Music.

Charles Hill

 Mr. Charles H. Hill, III, is Executive Vice President - Worldwide Human Resources of Pfizer Inc., since December 2010. He served as Senior Vice President, Human Resources for Worldwide Biopharmaceuticals Businesses from 2008 through December 2010. Vice President, Human Resources, Worldwide Pharmaceutical Operations from 2004 through 2008. Currently a Director of Zoetis and Chair of the Zoetis Compensation Committee.

Freda Lewis-Hall

 Dr. Freda C. Lewis-Hall, M.D., is Executive Vice President, Chief Medical Officer of Pfizer Inc., since December 2010. She served as Senior Vice President, Chief Medical Officer from May 2009 until December 2010. Previously, she was Chief Medical Officer and Executive Vice President, Medicines Development at Vertex Pharmaceuticals from June 2008 until May 2009. Dr. Lewis-Hall was Senior Vice President, U.S. Pharmaceuticals, Medical Affairs for Bristol-Myers Squibb Company from 2003 until May 2008.

Anthony Maddaluna

 Mr. Anthony J. Maddaluna is Executive Vice President; President, Pfizer Global Supply of Pfizer Inc., since January 2013. He was President, Pfizer Global Supply from 2011 until December 2012. Senior Vice President, Strategy & Supply Network Transformation from 2009 until December 2010. Vice President, Strategy & Supply Network Transformation from 2008 until 2009. Vice President and Team Leader, Europe from 1998 until 2008 including responsibility for global logistics and strategic planning from 2005 through 2008. Mr. Maddaluna held a number of positions of increasing responsibility in manufacturing before being named General Manager of Pfizer Pharmaceuticals Inc. in Puerto Rico from 1994 until 1998. Mr. Maddaluna represents Pfizer on the National Association of Manufacturers (NAM) and is a member of the NAM Executive Committee. Mr. Maddaluna joined Pfizer in 1975.

Laurie Olson

 Ms. Laurie J. Olson serves as the Executive Vice President - Strategy, Portfolio and Commercial Operations of Pfizer Inc., since July 2012. She was Senior Vice President - Strategy and Portfolio Management from 2011 until July 2012. Senior Vice President - Portfolio Management and Analytics from 2008 until 2010. Since joining Pfizer in 1987 as an Analyst in the Company's marketing research organization, Ms. Olson has served in a variety of marketing leadership positions with increasing responsibility in both the Company’s U.S. and global commercial organizations. She earned a Bachelor of Science degree in Economics from the State University of New York at Stony Brook and an MBA in Marketing from Hofstra University.

Sally Susman

 Ms. Sally Susman is Executive Vice President - Policy, External Affairs and Communications of Pfizer Inc., since December 2010. She served as Senior Vice President, Policy, External Affairs and Communications from December 2009 until December 2010. Senior Vice President and Chief Communications Officer from February 2008 until December 2009. Prior to joining Pfizer, Ms. Susman held senior level positions at The Estee Lauder Companies, including Executive Vice President from 2004 to January 2008.

Olivier Brandicourt

 Mr. Olivier Brandicourt is President and General Manager - Pfizer Emerging Markets and Established Products of Pfizer Inc., since June 1, 2012. He was President and General Manager of Pfizer Primary Care from 2009 until June 2012. In early 2009, served as President and General Manager of Pfizer Specialty Care. Senior Vice President and General Manager of U.S. Pratt Business Unit from 2007 until 2008. Managing Director of the United Kingdom/Ireland Pfizer subsidiary from 2004 to 2007. He is an Honorary Fellow of the Royal College of Physicians in London and a trustee of the Children's Aid Society of New York.

Geno Germano

 Mr. Geno J. Germano is President and General Manager - Pfizer Specialty Care and Oncology of Pfizer Inc., since December 2010. He was President and General Manager, Pfizer Specialty Care and Oncology since December 2010. President and General Manager, Specialty Care from October 2009 until December 2010. President, U.S. Pharmaceuticals and Women’s Health Care Unit, Wyeth Pharmaceuticals from 2008 through October 2009. President and General Manager, U.S. Pharmaceutical Business Unit, Wyeth Pharmaceuticals from 2007 through 2008. Executive Vice President and General Manager, Pharmaceutical Business Unit, Wyeth Pharmaceuticals from 2004 through 2007. Currently a Director of Zoetis, Member of the Board of Trustees for Albany College of Pharmacy and Health Sciences and Member of the Board of Directors of BIO – Biotechnology Industry Organization.

John Young

 Mr. John D. Young is President and General Manager - Primary Care of Pfizer Inc., since June 1, 2012. He was Primary Care Business Unit’s Regional President for Europe and Canada from 2009 until June 2012. UK Country Manager from 2007 until 2009. Since joining Pfizer in 1987, Mr. Young has held a number of positions of increasing responsibility in sales and marketing management before being appointed Country Manager for Australia/New Zealand in 2004.

George Lorch

 Mr. George A. Lorch is Lead Independent Director of Pfizer Inc. Mr. Lorch is Chairman Emeritus of Armstrong Holdings, Inc., a global manufacturer of flooring and ceiling materials, since 2000, having served as Chairman and Chief Executive Officer and in other executive capacities with Armstrong Holdings, Inc. and its predecessor, Armstrong World Industries, Inc., from 1993 to 2000. Director of Masonite International, Inc., a non-public company, and also a Director of HSBC Finance Co. and HSBC North America Holding Company, non-public, wholly owned subsidiaries of HSBC LLC. Director of The Williams Companies, Inc. from 2001 until 2011.

Dennis Ausiello

 Dr. Dennis A. Ausiello, M.D., is Independent Director of Pfizer Inc., since December 2006. He is Jackson Professor of Clinical Medicine at Harvard Medical School and Chief of Medicine at Massachusetts General Hospital since 1996. President of the Association of American Physicians in 2006. Member of the Institute of Medicine of the National Academies of Science and a Fellow of the American Academy of Arts and Sciences. Director of TARIS BioMedical, Inc. and of several non-profit organizations.

M. Anthony Burns

 Mr. M. Anthony Burns is Independent Director of Pfizer Inc., since 1988. He has been Chairman Emeritus since 2002, Chairman of the Board from 1985 to 2002, Chief Executive Officer from 1983 to 2000, and President from 1979 to 1999 of Ryder System, Inc., a provider of transportation and logistics services. Life Trustee of the University of Miami. Director of J. C. Penney Company, Inc. from 1988 to 2011; Stanley Black & Decker, Inc. from March 2010 until May 2010; and The Black & Decker Corporation from 2001 until March 2010.

W. Don Cornwell

 Mr. W. Don Cornwell is Independent Director of Pfizer Inc., since February 1997. He has been Chairman of the Board and Chief Executive Officer of Granite Broadcasting Corporation from 1988 until his retirement in August 2009 and Vice Chairman until December 2009. Granite Broadcasting Corporation filed for voluntary reorganization under Chapter 11 of the U.S. Bankruptcy Code in December 2006 and emerged from its restructuring in June 2007. Trustee of Big Brothers/Sisters of New York, Director of the Wallace Foundation from 2002 until 2012 and the M.S. Hershey School and Trust from 1995 until 2002.

Frances Fergusson

 Dr. Frances D. Fergusson, Ph.D., is Independent Director of Pfizer Inc., since September 25, 2009. Dr. Fergusson is President Emeritus of Vassar College since 2006 and President from 1986 to 2006. Served on the Mayo Clinic Board for 14 years, the last four years as its Chairman, and as President of the Board of Overseers of Harvard University from 2007 through 2008. Director of HSBC Bank USA from 1990 through 2008 and of Wyeth from 2005 until 2009. Serves as a Trustee and on the executive committees of The Getty Trust, The School of American Ballet and Second Stage Theatre.

William Gray

 Mr. William H. Gray, III, is Independent Director of Pfizer Inc., since June 2000. He has been Chairman of Gray Global Strategies, Inc., a business advisory firm. Co-Chairman of GrayLoeffler, LLC from 2009 to 2011, a business advisory and consulting firm. Chairman of the Amani Group, its predecessor, from 2004 through September 2009. Pastor Emeritus of the Bright Hope Baptist Church in Philadelphia since 2005. President and Chief Executive Officer of The College Fund/UNCF (Educational Assistance) from 1991 to 2004. U.S. Congressman from the Second District of Pennsylvania from 1979 to 1991, including service at various times as Budget Committee Chair and House Majority Whip. Director of J. P. Morgan Chase & Co. from 2002 to 2012 and Visteon Corporation from 2000 until January 2010.

Helen Hobbs

 Dr. Helen Hobbs, M.D., is Independent Director of Pfizer Inc., since December 12, 2011. She is Investigator of the Howard Hughes Medical Institute since 2002, a Professor of Internal Medicine and Molecular Genetics and Director of the McDermott Center for Human Growth and Development at the University of Texas Southwestern Medical Center. In 2007, Dr. Hobbs was elected to the National Academy of Sciences and received the Distinguished Scientist Award from the American Heart Association. In 2005, she became the first recipient of the Clinical Scientist Award from the American Heart Association, and was awarded Germany’s Heinrich Wieland Prize. Dr. Hobbs was elected to the Institute of Medicine in 2004 and the American Academy of Arts and Sciences in 2006 and received the International Society of Atherosclerosis Prize in 2012. She is a member of the American Society of Clinical Investigation and the Association of American Physicians.

Constance Horner

 Ms. Constance J. Horner is Independent Director of Pfizer Inc., since 1993. She was Guest Scholar from 1993 until 2005 at The Brookings Institution, an organization devoted to nonpartisan research, education and publication in economics, government, foreign policy and the social sciences. Commissioner of the U.S. Commission on Civil Rights from 1993 to 1998. Served at the White House as Assistant to President George H. W. Bush and as Director of Presidential Personnel from 1991 to 1993. Deputy Secretary, U.S. Department of Health and Human Services, from 1989 to 1991. Director of the U.S. Office of Personnel Management from 1985 to 1989. Fellow, National Academy of Public Administration, and Member of the Board of Trustees of the Prudential Foundation.

James Kilts

 Mr. James M. Kilts is Independent Director of Pfizer Inc., since September 27, 2007. He is Founding Partner, Centerview Capital, a private equity firm, since 2006. Vice Chairman, The Procter & Gamble Company, from 2005 to 2006. Chairman and Chief Executive Officer, The Gillette Company, from 2001 to 2005 and President, The Gillette Company, from 2003 to 2005. President and Chief Executive Officer, Nabisco Group Holdings Corporation, from 1998 until its acquisition in 2000. Currently Chairman of The Nielsen Company B.V. Supervisory Board and Non-Executive Director and Chairman of the Board of Nielsen Holdings N.V. Trustee of Knox College and the University of Chicago, and a member of the Board of Overseers of Weill Cornell Medical College. Director of New York Times Company from 2005 until 2008.

Suzanne Nora Johnson

 Ms. Suzanne Nora Johnson is Independent Director of Pfizer Inc., since September 27, 2007. She is Retired Vice Chairman, Goldman Sachs Group, Inc., since 2007. During her 21-year tenure with Goldman Sachs, she served in various leadership roles, including Chair of the Global Markets Institute, Head of Global Research, and Head of Global Healthcare. Board member of the American Red Cross, The Brookings Institution, the Carnegie Institution of Washington and the University of Southern California.

Stephen Sanger

 Mr. Stephen W. Sanger is Independent Director of Pfizer Inc., since February 1, 2009. He served as Chairman of General Mills, Inc., a packaged food producer and distributor, from 1995 until his retirement in 2008 and its Chief Executive Officer from 1995 to 2007. Former Chairman of the Grocery Manufacturers of America. Recipient of the Woodrow Wilson Award for Public Service in 2009. Chaired the Fiscal Policy Committee of the Business Roundtable and served as a director of Catalyst. Director of General Mills, Inc. from 1992 until 2008 and of Target Corporation from 1996 to 2013.

Marc Tessier-Lavigne

 Dr. Marc Tessier-Lavigne, Ph.D., is Independent Director of Pfizer Inc., since December 12, 2011. He is President of The Rockefeller University since March 2011. Between 2003 and 2011, held positions of increasing responsibility at Genentech, where he became Executive Vice President, Research, and Chief Scientific Officer. Susan B. Ford Professor in the School of Humanities and Sciences, and Professor of Biological Sciences and of Neurology and Neurological Sciences, at Stanford University from 2001 to 2003, and a faculty member at the University of California, San Francisco from 1991 to 2001. In addition, Dr. Tessier-Lavigne was a Howard Hughes Medical Institute Investigator from 1994 to 2003. Member of the National Academy of Sciences and its Institute of Medicine, and a Fellow of the Royal Society (UK), the Royal Society of Canada, the Academy of Medical Sciences (UK) and the American Association for the Advancement of Science.

Insider Trading

Name Shares Traded Price

READ IAN C

 200 $29.49

READ IAN C

 8,700 $29.36

SCHULMAN AMY W

 3,999 $29.36

READ IAN C

 1,800 $29.37

READ IAN C

 2,900 $29.40

D AMELIO FRANK A

 5,103 $29.36

READ IAN C

 700 $29.47

SCHULMAN AMY W

 805 $29.44

READ IAN C

 10,503 $29.30

D AMELIO FRANK A

 10,913 $29.33

READ IAN C

 19,400 $29.48

SCHULMAN AMY W

 3,802 $29.39

SCHULMAN AMY W

 4,500 $29.29

D AMELIO FRANK A

 6,342 $29.41

READ IAN C

 705 $29.32

D AMELIO FRANK A

 900 $29.28

READ IAN C

 200 $29.42

D AMELIO FRANK A

 8,106 $29.34

D AMELIO FRANK A

 5,693 $29.31

SCHULMAN AMY W

 10,598 $29.35

READ IAN C

 900 $29.46

SCHULMAN AMY W

 300 $29.46

SCHULMAN AMY W

 3,592 $29.42

D AMELIO FRANK A

 100 $29.42

READ IAN C

 1,302 $29.33
» Full list on Insider Trading
Search Stocks